bazedoxifene has been researched along with digitoxin in 1 studies
| Studies (bazedoxifene) | Trials (bazedoxifene) | Recent Studies (post-2010) (bazedoxifene) | Studies (digitoxin) | Trials (digitoxin) | Recent Studies (post-2010) (digitoxin) |
|---|---|---|---|---|---|
| 307 | 69 | 249 | 5,259 | 90 | 219 |
| Protein | Taxonomy | bazedoxifene (IC50) | digitoxin (IC50) |
|---|---|---|---|
| STAT3, partial | Homo sapiens (human) | 0.7 | |
| Bile salt export pump | Homo sapiens (human) | 10 | |
| Sodium/potassium-transporting ATPase subunit alpha-1 | Homo sapiens (human) | 0.008 | |
| Sodium/potassium-transporting ATPase subunit beta-1 | Homo sapiens (human) | 0.008 | |
| Replicase polyprotein 1ab | Severe acute respiratory syndrome coronavirus 2 | 0.23 | |
| Sodium/potassium-transporting ATPase subunit alpha-3 | Homo sapiens (human) | 0.008 | |
| Sodium/potassium-transporting ATPase subunit beta-2 | Homo sapiens (human) | 0.008 | |
| Sodium/potassium-transporting ATPase subunit alpha-2 | Homo sapiens (human) | 0.008 | |
| Sodium/potassium-transporting ATPase subunit alpha-1 | Canis lupus familiaris (dog) | 0.008 | |
| Sodium/potassium-transporting ATPase subunit beta-3 | Homo sapiens (human) | 0.008 | |
| Sodium/potassium-transporting ATPase subunit gamma | Homo sapiens (human) | 0.008 | |
| Sodium/potassium-transporting ATPase subunit alpha-4 | Homo sapiens (human) | 0.008 | |
| Solute carrier organic anion transporter family member 4C1 | Homo sapiens (human) | 0.12 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Byun, SY; Choi, I; Jeon, S; Kim, S; Ko, M; Lee, J; Park, S; Shum, D | 1 |
1 other study(ies) available for bazedoxifene and digitoxin
| Article | Year |
|---|---|
Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs.
Topics: Animals; Anti-Inflammatory Agents; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Coronavirus Infections; COVID-19; Drug Evaluation, Preclinical; Drug Repositioning; Humans; Niclosamide; Pandemics; Pneumonia, Viral; Pregnenediones; SARS-CoV-2; Vero Cells | 2020 |